Search Press releases Keywords From To 4 Mar 2024 UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases Read More 28 Feb 2024 UCB on Growth Path for a Decade Plus Read More 9 Feb 2024 Latest analyses of bimekizumab phase 3 studies in moderate to severe hidradenitis suppurativa to be presented at EHSF 2024 Read More 6 Feb 2024 Transparency notification FMR LLC Read More 8 Jan 2024 UCB announces European Commission approval of RYSTIGGO[®]▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe Read More 27 Dec 2023 BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Read More Pagination First page Previous page Previous … Page 27 Page 28 Page 29 Page 30 Current page 31 Page 32 Page 33 Page 34 Page 35 … Page 31 of 67 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe